<SEC-DOCUMENT>0001731122-23-000552.txt : 20230403
<SEC-HEADER>0001731122-23-000552.hdr.sgml : 20230403
<ACCEPTANCE-DATETIME>20230403092010
ACCESSION NUMBER:		0001731122-23-000552
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230330
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230403
DATE AS OF CHANGE:		20230403

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enochian Biosciences Inc
		CENTRAL INDEX KEY:			0001527728
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				452259340
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38758
		FILM NUMBER:		23790909

	BUSINESS ADDRESS:	
		STREET 1:		CENTURY CITY MEDICAL PLAZA
		STREET 2:		2080 CENTURY CITY EAST
		CITY:			SUITE 906 LOS ANGELES
		STATE:			CA
		ZIP:			90067
		BUSINESS PHONE:		45 39179840

	MAIL ADDRESS:	
		STREET 1:		CENTURY CITY MEDICAL PLAZA
		STREET 2:		2080 CENTURY CITY EAST
		CITY:			SUITE 906 LOS ANGELES
		STATE:			CA
		ZIP:			90067

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DanDrit Biotech USA, Inc.
		DATE OF NAME CHANGE:	20140214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Putnam Hills Corp.
		DATE OF NAME CHANGE:	20110810
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>e4510_8-k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:ENOB="http://enochianbio.com/20230330">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_ENOB_enochianbio.com_20230330 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20230330_20230330 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001527728 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-03-30to2023-03-30" name="dei:EntityCentralIndexKey">0001527728</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-03-30to2023-03-30" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="enob-20230330.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-03-30to2023-03-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-30</xbrli:startDate>
        <xbrli:endDate>2023-03-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>UNITED
STATES<br />
SECURITIES AND EXCHANGE COMMISSION</b></span><b><span style="font-family: Times New Roman, Times, Serif"><br />
<span style="font-size: 12pt">Washington, DC 20549</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_908_edei--DocumentType_c20230330__20230330_zVB1rzl2T1Ih"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Pursuant
to Section 13 or 15(d) of the<br />
Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Date
of Report (Date of earliest event reported): <b><span id="xdx_90B_edei--DocumentPeriodEndDate_c20230330__20230330_z3Xb6upO9Mkc"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 30, 2023</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 24pt"><b><span style="text-decoration: underline"><span id="xdx_908_edei--EntityRegistrantName_c20230330__20230330_z0WPAuqKjyvg"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" name="dei:EntityRegistrantName">ENOCHIAN
BIOSCIENCES INC.</ix:nonNumeric></span></span></b></span><b><span style="text-decoration: underline"><span style="font-family: Times New Roman, Times, Serif"><br />
</span></span></b><span style="font-family: Times New Roman, Times, Serif">(Exact name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 34%; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20230330__20230330_zYu9bxbbX4a2"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 32%; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityFileNumber_c20230330__20230330_z9dVqsn3I199"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" name="dei:EntityFileNumber">000-54478</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 32%; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20230330__20230330_zHwhg07YXKEk"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" name="dei:EntityTaxIdentificationNumber">45-2559340</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    File Number)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20230330__20230330_zlp2XGrYm3J1"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" name="dei:EntityAddressAddressLine1">1927
Paseo Rancho Castilla</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_909_edei--EntityAddressCityOrTown_c20230330__20230330_z8Id5wpBtBn3"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" name="dei:EntityAddressCityOrTown">Los
Angeles</ix:nonNumeric></span>,&#160;<span id="xdx_903_edei--EntityAddressStateOrProvince_c20230330__20230330_zviZ0q639QK5"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span>&#160;<span id="xdx_90B_edei--EntityAddressPostalZipCode_c20230330__20230330_zb6B43AGb4l5"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" name="dei:EntityAddressPostalZipCode">90032</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Address
of principal executive offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration: underline">+1<span id="xdx_903_edei--CityAreaCode_c20230330__20230330_zB6SshZOXGIg"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" name="dei:CityAreaCode">(305)</ix:nonNumeric></span>
<span id="xdx_907_edei--LocalPhoneNumber_c20230330__20230330_zZJceBvkmkE"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" name="dei:LocalPhoneNumber">918-1980</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--WrittenCommunications_c20230330__20230330_zU9y6GyXkuEa"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--SolicitingMaterial_c20230330__20230330_znNaVn21KhVd"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant
    to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--PreCommencementTenderOffer_c20230330__20230330_zy56P2baSVfh"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--PreCommencementIssuerTenderOffer_c20230330__20230330_z2pK3zWoLmrk"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">Securities registered
pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 66%; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Title
    of Each Class </span></b></span></td>
    <td style="white-space: nowrap; width: 1%; padding-right: 5.65pt; padding-left: 5.65pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 6%; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Trading
    Symbol </span></b></span></td>
    <td style="white-space: nowrap; width: 1%; padding-right: 5.65pt; padding-left: 5.65pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; width: 26%; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Name
    of Each Exchange on Which Registered </span></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--Security12bTitle_c20230330__20230330_ztaA8oIoMuf9"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" name="dei:Security12bTitle">Common
    Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="white-space: nowrap; padding-right: 5.65pt; padding-left: 5.65pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--TradingSymbol_c20230330__20230330_zwehloruoOhe"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" name="dei:TradingSymbol">ENOB</ix:nonNumeric></span></span></td>
    <td style="white-space: nowrap; padding-right: 5.65pt; padding-left: 5.65pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--SecurityExchangeName_c20230330__20230330_zWY1p5siZ1t6"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">Emerging growth
company <span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20230330__20230330_zPUWd0Y00Q2i"><ix:nonNumeric contextRef="From2023-03-30to2023-03-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Item 1.01 Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information under Item 3.02
below is incorporated by reference into this Item 1.01.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Item 3.02 Unregistered
Sales of Equity Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 30, 2023, Enochian Biosciences
Inc., a Delaware corporation (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;) closed a private placement (the
&#8220;<span style="text-decoration: underline">Private Placement</span>&#8221;) of (i) 2,178,070 shares (the &#8220;<span style="text-decoration: underline">Shares</span>&#8221;)
of its common stock, par value $0.0001 per share (&#8220;<span style="text-decoration: underline">Common Stock</span>&#8221;) and (ii)
1,089,036 common stock purchase warrants (the &#8220;<span style="text-decoration: underline">Warrants</span>&#8221; and together with
the Shares, the &#8220;<span style="text-decoration: underline">Securities</span>&#8221;), which represents 50% warrant coverage, at a
purchase price of $1.14 per share, for aggregate proceeds to the Company of $2,483,000. The Warrants are exercisable for five years from
the date of issuance and have an exercise price of $1.14 per share, payable in cash. The Private Placement was completed pursuant to Regulation
S promulgated under the Securities Act of 1933, as amended (&#8220;<span style="text-decoration: underline">Regulation S</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the Private
Placement, each investor executed a subscription agreement in the form of Exhibit 10.1 attached hereto. Each subscription agreement contains
customary representations and warranties of the Company and of each investor, including that all investors purchasing the Securities are
not &#8220;U.S. persons&#8221; as defined by Rule 902 of Regulation S. The Private Placement was made directly by the Company and no underwriter
or placement agent was engaged by the Company. The Company did not engage in general solicitation or advertising and did not offer the
Securities to the public in connection with the Private Placement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The foregoing description of the
Subscription Agreement and Warrants does not purport to be complete, and is qualified in its entirety by reference to the form of subscription
agreement and form of Warrant attached hereto as Exhibits 10.1 and 4.1, which are incorporated by reference herein. The disclosure contained
in this Current Report on Form 8-K does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company,
and is made only as required under applicable rules for filing current reports with the Securities and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On April
3, 2023, the Company published a letter to shareholders. A copy of the letter is furnished as Exhibit 99.1 to this Current Report on Form
8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The information
included in this Item 8.01 and in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the &#8220;<span style="text-decoration: underline">Exchange Act</span>&#8221;), or otherwise subject to the liabilities
of that Section or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such a filing.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Item 9.01 Financial Statements and Exhibits</b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="border-bottom: black 1pt solid; padding: 0pt; width: 10%; text-indent: 0pt"><span style="font-size: 10pt">Exhibit No.</span></td>
<td style="padding: 0pt; width: 2%; text-indent: 0pt">&#160;</td>
<td style="border-bottom: black 1pt solid; padding: 0pt; width: 88%; text-indent: 0pt"><span style="font-size: 10pt">Exhibit</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt">4.1</span></td>
<td style="padding: 0pt; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; text-indent: 0pt"><a href="e4510_ex4-1.htm"><span style="font-size: 10pt">Form of Warrant</span></a></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt">10.1</span></td>
<td style="padding: 0pt; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; text-indent: 0pt"><a href="e4510_ex10-1.htm"><span style="font-size: 10pt">Form of Subscription Agreement</span></a></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0pt; text-align: center; text-indent: 0pt">&#160;99.1</td>
<td style="padding: 0pt; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; text-indent: 0pt"><a href="e4510_ex99-1.htm">Shareholder Letter, dated April 3, 2023&#160;</a></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0pt; text-align: center; text-indent: 0pt"><span style="font-size: 10pt">104</span></td>
<td style="padding: 0pt; text-indent: 0pt">&#160;</td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 45pt 0 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 45pt 0 0; text-align: center"><b></b></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 45pt 0 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>ENOCHIAN BIOSCIENCES, INC.</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; width: 50%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">By: </span></td>
    <td style="vertical-align: top; width: 45%"><span style="font-size: 10pt">/s/ Luisa Puche</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; vertical-align: top"><span style="font-size: 10pt">Name: Luisa Puche<br />
Title: Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: April 3, 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">3</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5lppWRembFi1iFSkivga7lWCbLZv4dyRvaWwRl4VlmflmhBiIjFa6RobTosjhgE1bK4dQYIWM5ozeka43Cfhb4EVbx8q47v2BKXkGPTMJo5nyQme9a4tlAnI8lKNhPAI5TSYzmG9F8NVTMpUu0TitalCmhD1Tyxqd4lefcFBPMtS8uqojstVkEohC2ctviGUUw47u6kF8tZDnqQgG3QQiY7q135qbddTAssbGd9ke/W/wARaySUY= -->


</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>e4510_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 10pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NEITHER THIS WARRANT NOR THE SECURITIES FOR
WHICH THIS WARRANT IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE, IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES
ACT&rdquo;), AND ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH
EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>enochian
biosciences inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Warrant Shares: [ ]</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">Issue Date:
    March [ ], 2023</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 252pt; text-indent: 36pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">THIS COMMON STOCK PURCHASE WARRANT (this &ldquo;<U>Warrant</U>&rdquo;)
certifies that, for value received, [ ] (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations
on exercise and the conditions hereinafter set forth, at any time after the Issue Date (the &ldquo;<U>Initial Exercise Date</U>&rdquo;)
and on or prior to the close of business on the Termination Date (as defined below) but not thereafter, to subscribe for and purchase
from Enochian Biosciences Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), of up to [ ] shares (subject to adjustment
hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of the Company&rsquo;s Common Stock, par value $0.0001 per share (&ldquo;<U>Common
Stock</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><U>Section 1</U>.<U> Exercise; Termination Date</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">a) <U>Exercise of Warrant</U>. Exercise of the
purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise
Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may
designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of
a duly executed copy of the Notice of Exercise Form annexed hereto as <U>Annex A</U>; and, within three (3) Business Days of the
date said Notice of Exercise is delivered to the Company, the Company shall have received payment of the aggregate Exercise Price
of the shares thereby purchased by wire transfer or cashier&rsquo;s check drawn on a United States bank. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has
purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation within three (3) Business Days of the date the final Notice of Exercise
is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant
Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in
an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of
Exercise Form within two (2) Business Days of receipt of such notice. In the event of any dispute or discrepancy, the records of
the Holder shall be controlling and determinative in the absence of manifest error. <B>The Holder and any assignee, by acceptance
of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion
of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than
the amount stated on the face hereof. </B>As used herein, &ldquo;Business Day&rdquo; means any day except Saturday, Sunday or any
other day on which commercial banks located in the State of Delaware are authorized or required by law to be closed for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">b) <U>Exercise Price</U>. The exercise price (the &ldquo;<U>Exercise Price</U>&rdquo;) of this Warrant
shall be $1.14 per Warrant Share, subject to adjustment hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">c) <U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-indent: 36pt">i. <U>Delivery of Certificates Upon
Exercise</U>. Certificates for the Warrant Shares purchased or exercised hereunder shall be transmitted by the Company&rsquo;s
transfer agent to the Holder by crediting the account of the Holder&rsquo;s broker with the Depository Trust Company through its
Deposit Withdrawal Agent Commission (&ldquo;<U>DWAC</U>&rdquo;) system if the Company is then a participant in such system and
there is an effective registration statement permitting the resale of the Warrant Shares and otherwise by physical delivery to
the address specified by the Holder in the Notice of Exercise within three (3) Business Days from the delivery to the Company of
the Notice of Exercise Form, surrender of this Warrant (if required), and payment of the aggregate Exercise Price (unless cashless
exercise is utilize) as set forth above (the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). This Warrant shall be deemed to
have been exercised on the date the Exercise Price is received by the Company (or notice of cashless exercise is received). The
Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed
to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised by payment to
the Company of the Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to <U>Section 1(c)(v)</U> prior
to the issuance of such shares, have been paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-indent: 36pt">ii. <U>Delivery of New Warrants Upon
Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender
of this Warrant, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to Holder a new
Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant
shall in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-indent: 36pt">iii. <U>Rescission Rights</U>. If the
Company fails to cause the Company&rsquo;s transfer agent to transmit to the Holder a certificate or the certificates representing
the Warrant Shares pursuant to <U>Section 1(c)(i)</U> by the Warrant Share Delivery Date, then, the Holder will have the right
to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-indent: 36pt">iv. <U>No Fractional Shares or Scrip</U>.
No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction
of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either
pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-indent: 36pt">v. <U>Charges, Taxes and Expenses</U>.
Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such
certificates shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that in the event certificates for Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder,
and such other documentation as the Company may require regarding the investor status of the assignee, as a condition thereto,
the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-indent: 36pt">vi. <U>Closing of Books</U>. The Company
will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the
terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">d) <U>Termination Date</U>. This Warrant shall
be exercisable from the Initial Exercise Date until March [ ], 2028.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><U>Section 2</U>. <U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">a) <U>Fundamental Transaction</U>. If, at any
time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any
merger or consolidation of the Company with or into another person, (ii) the Company, directly or indirectly, effects any sale,
lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series
of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company
or another person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares
for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv)
the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged
for other securities, cash or property, (v) the Company, directly or indirectly, in one or more related transactions consummates
a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with another person or group of persons whereby such other person or group acquires more than
50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other person or other persons
making or party to, or associated or affiliated with the other persons making or party to, such stock or share purchase agreement
or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this
Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder, the number, class, and series of shares of
stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number
of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction. For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative
value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities,
cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any
successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;)
to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance
with the provisions of this <U>Section 2(a)</U> pursuant to written agreements in form and substance reasonably satisfactory to
the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option
of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital
stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise
of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and
with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the
relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock,
such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance
to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted
for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction
Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents
with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">b) <U>Stock Dividends and Splits</U>. If the
Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions
on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for
avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides
outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding
shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares of the Common Stock any shares
of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator
shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and
of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number
of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged, subject to the limitation on fractional shares in Section 2(d)(iv). Any adjustment made pursuant
to this Section 2(b) shall become effective immediately after the record date for the determination of stockholders entitled to
receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision,
combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">c) <U>Calculations</U>. All calculations under
this <U>Section 2</U> shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: 36pt">d) <U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-indent: 36pt">i. <U>Adjustment to Exercise Price</U>.
Whenever the Exercise Price is adjusted pursuant to any provision of this <U>Section 2</U>, the Company shall promptly deliver
to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement
of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-indent: 36pt">ii. <U>Notice to Allow Exercise by
Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the
Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize
the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of
any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially
all of the assets of the Company, of any compulsory share exchange whereby the Common Stock is converted into other securities,
cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the
affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its
last facsimile number of email address as it shall appear upon the Warrant Register of the Company, at least five (5) calendar
days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is
to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken,
the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights
or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share
exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of
record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such
reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or
any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in
such notice. The Holder is entitled to exercise this Warrant during the period commencing on the date of such notice to the effective
date of the event triggering such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><U>Section 3</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">a) <U>Transferability</U>. Subject to compliance
with any applicable securities laws and the reasonable conditions and documentation required by the Company, this Warrant and all
rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender
of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant
substantially in the form attached hereto as <U>Annex B</U> (the &ldquo;<U>Assignment Form</U>&rdquo;), duly executed by the Holder
or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender
and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or
assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue
to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
The Warrant, if properly assigned, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant
issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">b) <U>New Warrants</U>. This Warrant may be divided
or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice
specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject
to compliance with <U>Section 3(a)</U>, as to any transfer which may be involved in such division or combination, the Company shall
execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with
such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date and shall be identical with
this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">c) <U>Warrant Register</U>. The Company shall
register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;),
in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant
as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes,
absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><U>Section 4</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">a) <U>No Rights as Stockholder Until Exercise</U>.
This Warrant does not entitle the Holder to any voting rights or other rights as a stockholder of the Company prior to the exercise
hereof as set forth in <U>Section 1(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">b) <U>Loss, Theft, Destruction or Mutilation
of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft,
destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or
destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting
of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and
deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">c) <U>Saturdays, Sundays, Holidays, etc</U>.
If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be
a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">d) <U>Authorized Shares</U>. The Company covenants
that, during the period the Warrant is outstanding, it will reserve, from its authorized and unissued Common Stock, a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged
with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise
of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that
such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements
of the business market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued
upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by
this Warrant, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created
by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such
issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">e) <U>Governing Law</U>. All questions concerning
the construction, validity, enforcement and interpretation of this Warrant shall be determined by applying the laws of the State
of Delaware, without regard to its conflicts of laws provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">f) <U>Restrictions</U>. The Holder acknowledges
that the Warrant Shares acquired upon the exercise of this Warrant will have restrictions upon resale imposed by state and federal
securities laws unless (i) such Warrant Shares are registered; or (ii) the resale of the Warrant Shares satisfies an exemption
from registration under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">g) <U>Nonwaiver and Expenses</U>. No course of
dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or
otherwise prejudice Holder&rsquo;s rights, powers or remedies, notwithstanding the fact that all rights hereunder terminate on
the Termination Date. If the Company willfully and knowingly fails to comply with any provision of this Warrant, which results
in any material damages to the Holder, the Company shall pay to Holder such amounts as shall be sufficient to cover any costs and
expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by
Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">h) <U>Notices</U>. All notices and other communications
from the Company to the Holder of this Warrant shall be sent by electronic transmission or overnight courier or shall be mailed
by first class registered or certified mail, postage prepaid, at such address as may have been furnished to the Company in writing
by such Holder. All such notices and communications shall, when mailed, be effective when deposited in the mails and, when sent
by electronic transmission or overnight courier, delivered, be effective when received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">i) <U>Limitation of Liability</U>. No provision
hereof, in the absence of any affirmative action by Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration
herein of the rights or privileges of Holder, shall give rise to any liability of Holder for the purchase price of any Common Stock
or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">j) <U>Successors and Assigns</U>. Subject to
applicable federal and state securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit
of and be binding upon the successors of the Company and the successors and permitted assigns of Holder. The provisions of this
Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and shall be enforceable by the Holder
or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">k) <U>Amendment</U>. This Warrant may be modified
or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">m) <U>Severability</U>. Wherever possible, each
provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision
of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such
prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">n) <U>Headings</U>. The headings used in this
Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">[SIGNATURE PAGE FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">IN WITNESS WHEREOF, the Company has caused this
Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>ENOCHIAN BIOSCIENCES INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ANNEX A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To:
enochian biosciences INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">(1) The undersigned hereby elects to purchase
________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(2) Payment shall take the
form of lawful money of the United States:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">(3) Please issue a certificate or certificates
representing said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 108pt">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Warrant Shares shall be delivered to the following DWAC Account
Number or by physical delivery of a certificate to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 108pt">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 108pt">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 108pt">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 108pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">(4) <U>Accredited Investor</U>. The undersigned
is an &ldquo;accredited investor&rdquo; as defined in Rule 501(a) of Regulation D, promulgated under the Securities Act of 1933,
as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name of Investing Entity: ___________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Signature of Authorized Signatory of Investing Entity</I>: _____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name of Authorized Signatory: _______________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title of Authorized Signatory: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Date: ___________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ANNEX B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(To assign the foregoing warrant, execute<BR>
this form and supply required information.<BR>
Do not use this form to exercise the Warrant.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">FOR VALUE RECEIVED, [____] all of or [_______]
shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">_______________________________________________
whose address is</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">_______________________________________________________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">_______________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Dated: ______________, ___________</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 16%; text-align: justify"><FONT STYLE="font-size: 10pt">Holder&rsquo;s Signature:</FONT></TD>
    <TD STYLE="width: 33%; text-align: justify"><FONT STYLE="font-size: 10pt">_______________________________</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Holder&rsquo;s Address:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">_______________________________</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">_______________________________</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Signature Guaranteed: ___________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">NOTE: The signature to this Assignment Form must correspond with
the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed
by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should file
proper evidence of authority to assign the foregoing Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>e4510_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>EXHIBIT 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">SUBSCRIPTION AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">This SUBSCRIPTION AGREEMENT (this
&ldquo;<U>Subscription Agreement</U>&rdquo;) is made by and between Enochian BioSciences Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
and the other signatories listed on the signature pages hereto (each, a &ldquo;<U>Subscriber</U>&rdquo;, and collectively, the &ldquo;<U>Subscribers</U>&rdquo;)
as of March ___, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">WHEREAS, subject to the terms and
conditions set forth in this Subscription Agreement, and pursuant to Regulation S under the Securities Act of 1933, as amended (the &ldquo;<U>Securities
Act</U>&rdquo;), the Company desires to issue and sell to each Subscriber, and each Subscriber desires to purchase from the Company, securities
of the Company as more fully described in this Subscription Agreement, in a private placement to Persons (as defined below) who are not
U.S. Persons under Regulation S (the &ldquo;<U>Offering</U>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">WHEREAS, each Subscriber understands
that the Offering is being made without registration of the securities under the Securities Act, or any securities law of any state of
the United States or of any other jurisdiction, and is being made to only non-U.S. Persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">NOW, THEREFORE, for and in consideration
of the premises and the mutual covenants hereinafter set forth, the parties hereto do hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subscription
for Securities</U>. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subscription
</U>for Securities. Subject to the terms and conditions hereinafter set forth, each Subscriber hereby irrevocably subscribes for and
agrees to purchase the number of (i) shares set forth next to such Subscriber&rsquo;s name on the signature page a hereto (the &ldquo;<U>Shares</U>&rdquo;)
of the Company&rsquo;s common stock, $0.0001 par value per share (&ldquo;<U>Common Stock</U>&rdquo;) and (ii) Common Stock purchase warrants
(the &ldquo;<U>Warrants</U>&rdquo; and together with the Shares, the &ldquo;<U>Securities</U>&rdquo;) at a price per Share equal to $1.14 (the &ldquo;<U>Purchase Price</U>&rdquo;), and the Company agrees to sell such Securities to such Subscriber for the Purchase Price,
subject to the Company&rsquo;s right, in its sole discretion, to reject this subscription, in whole or in part, at any time prior to
the Closing (as defined below). Each Subscriber acknowledges that such Subscriber is not entitled to cancel, terminate or revoke this
Subscription Agreement. Each Subscriber further acknowledges that the Securities will be subject to restrictions on transfer as set forth
in this Subscription Agreement. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Terms
of Subscription</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment</U>.
Each Subscriber shall make payment for the Securities to an account designated by the Company in an amount equal to the Purchase Price
by wire transfer of immediately available funds at or prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Acceptance
of Subscription and Issuance of Securities. </U>It is understood and agreed that the Company shall have the sole right, at its complete
discretion, to accept or reject this subscription, in whole or in part, for any reason and that the same shall be deemed to be accepted
by the Company only when it is signed by a duly authorized officer of the Company and delivered to each Subscriber at the Closing (as
defined below). Notwithstanding anything in this Subscription Agreement to the contrary, the Company shall have no obligation to issue
any of the Securities to any Person who is a resident of a jurisdiction in which the issuance of Securities to such Person would constitute
a violation of securities, &ldquo;blue sky&rdquo;, or other similar laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing</U><FONT STYLE="font-size: 10pt">.
The Offering may be consummated at such place (or by electronic transmission) as may be reasonably determined by the Company (the &ldquo;<U>Closing</U>&rdquo;)
to occur on a date and at a time as may be mutually acceptable to the Company and each Subscriber, subject to satisfaction of the terms
herein. Three days prior to Closing, the Company shall inform each Subscriber in writing of the Purchase Price as determined pursuant
to <U>Section 1(a) </U>and the date and time of Closing, which shall be binding upon the Company and each Subscriber.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
Deliverables</U><FONT STYLE="font-size: 10pt">. At the Closing: (i) Each Subscriber shall deliver the Purchase Price; and (ii) the Company
shall deliver a share certificate representing the Shares and a Warrant to such Subscriber that bears an appropriate legend referring
to the fact that the Securities are subject to transfer restrictions as set forth in the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 20pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of Subscriber</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Each Subscriber represents and
warrants to the Company that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reliance
on Exemptions</U><FONT STYLE="font-size: 10pt">. Such Subscriber understands that the Securities are being offered and sold in reliance
upon specific exemptions from registration provided in the Securities Act, and acknowledges that the Offering has not been reviewed by
the Securities and Exchange Commission or any state agency because it is intended to be an offering exempt from the registration requirements
of the Securities Act pursuant to Regulation S under the Securities Act. Such Subscriber understands that the Company is relying upon,
and intends that the Company rely upon, the truth and accuracy of, and such Subscriber&rsquo;s compliance with, the representations,
warranties, agreements, acknowledgments and understandings of such Subscriber set forth herein in order to determine the availability
of such exemptions and the eligibility of Subscriber to acquire the Securities. The Company may only make offers to sell the Securities
to an individual, corporation, association, general or limited partnership, joint venture, trust, estate, limited liability company,
other legal entity or organization, or the foreign equivalent of any of the foregoing (each, a &ldquo;<U>Person</U>&rdquo;) outside the
United States in this Offering and, if applicable, at the time any buy order is originated, the buyer is outside the United States. Such
Subscriber has not received an offer to purchase Securities inside the United States and will not originate a buy order inside the United
States. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-U.S. Person</U><FONT STYLE="font-size: 10pt">(c)&#9;.
Such Subscriber is not and is not acquiring the securities for the account or benefit of any of the following (each, a &ldquo;<U>U.S.
Person</U>&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: 36pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
natural person resident in the United States;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
partnership or corporation organized or incorporated under the laws of the United States;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;an
estate of which any executor or administrator is a U.S. Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
trust of which any trustee is a U.S. Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;an
agency or branch of a foreign entity located in the United States;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account
any of the foregoing; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
partnership or corporation (A) organized or incorporated under the laws of any foreign jurisdiction, and (B) formed by a U.S. Person principally
for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned,
by accredited investors (as defined in Regulation D under the Securities Act) who are not natural persons, estates or trusts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment
Purpose</U><FONT STYLE="font-size: 10pt">. The Securities are being purchased for such Subscriber&rsquo;s own account, for investment
purposes only and not with a view to sale or resale, distribution or fractionalization of the securities under applicable U.S. federal
or state securities laws. Such Subscriber is not acquiring such securities for the account or benefit of any U.S. Person and was not
organized for the specific purpose of acquiring such securities. Such Subscriber will not (i) resell or offer to resell the securities,
or any portion thereof, or (ii) engage in hedging transactions, in each case, except in accordance with the terms of this Agreement and
in accordance with Regulation S under the Securities Act, pursuant to registration under the Securities Act or pursuant to an available
exemption from registration under the Securities Act and otherwise in compliance with all applicable securities laws. Furthermore, prior
to engaging in any hedging transaction or any resale of the securities, or any portion thereof, by such Subscriber, such Subscriber shall
provide the Company with an opinion of counsel acceptable to the Company in its sole discretion and in a form acceptable to the Company
in its sole discretion, that any such proposed sale or hedging transaction is in compliance with the Securities Act or an exemption therefrom.
Such Subscriber has no contract, undertaking, agreement, or arrangement with any Person to sell, distribute, transfer, or pledge to such
Person or anyone else the Securities which such Subscriber hereby subscribes to purchase, or any interest therein, and such Subscriber
has no present plans to enter into any such contract, undertaking, agreement, or arrangement. Such Subscriber agrees that the Company
and its affiliates shall not be required to give effect to any purported transfer of such Securities except upon compliance with the
foregoing restrictions. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Risk
of Investment</U><FONT STYLE="font-size: 10pt">. Such Subscriber recognizes that the purchase of the Securities involves a high degree
of risk in that: (i) an investment in the Company is highly speculative and only investors who can afford the loss of their entire investment
should consider investing in the Company and the Securities; (ii) transferability of the Securities is limited; and (iii) the Company
may require substantial additional funds to operate its business and there can be no assurance that the Offering will be completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Proceeds</U><FONT STYLE="font-size: 10pt">. Such Subscriber understands that the net proceeds of the Offering will be used in the
development of the Company&rsquo;s therapies, and for working capital and general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Prior
Investment Experience</U><FONT STYLE="font-size: 10pt">. Such Subscriber understands the business in which the Company is engaged and
has such knowledge and experience in business and financial matters that such Subscriber is capable of evaluating the merits and risks
of the investment in the Securities. Such Subscriber has prior investment experience, and Subscriber recognizes the highly speculative
nature of this investment. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Information
and Non-Reliance</U><FONT STYLE="font-size: 10pt">. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
Subscriber acknowledges that such Subscriber has carefully reviewed this Subscription Agreement, which such Subscriber acknowledges has
been provided to such Subscriber. Such Subscriber has been given the opportunity to ask questions of, and receive answers from, the Company
concerning the terms and conditions of this Offering and the Subscription Agreement and to obtain such additional information, to the
extent the Company possesses such information or can acquire it without unreasonable effort or expense, necessary to verify the accuracy
of same as such Subscriber reasonably desires in order to evaluate the investment. Such Subscriber understands the Subscription Agreement,
and such Subscriber has had the opportunity to discuss any questions regarding the Subscription Agreement with such Subscriber&rsquo;s
counsel or other advisor. Notwithstanding the foregoing, the only information upon which such Subscriber has relied is that set forth
in the Subscription Agreement and the results of independent investigation by such Subscriber. Such Subscriber has received no representations
or warranties from the Company, its employees, agents or attorneys in making this investment decision other than as set forth in the Subscription
Agreement. Such Subscriber does not desire to receive any further information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
Subscriber represents that it is not relying on (and will not at any time rely on) any communication (written or oral) of the Company,
as investment advice or as a recommendation to purchase the Securities, it being understood that information and explanations related
to the terms and conditions of the Securities and the Subscription Agreement shall not be considered investment advice or a recommendation
to purchase the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
Subscriber confirms that the Company has not (i) given any guarantee or representation as to the potential success, return, effect or
benefit (either legal, regulatory, tax, financial, accounting or otherwise) an of investment in the Securities or (ii) made any representation
to such Subscriber regarding the legality of an investment in the Securities under applicable legal investment or similar laws or regulations.
In deciding to purchase the Securities, such Subscriber is not relying on the advice or recommendations of the Company and such Subscriber
has made its own independent decision that the investment in the Securities is suitable and appropriate for such Subscriber.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax
Consequences<FONT STYLE="font-size: 10pt">.</FONT></U><FONT STYLE="font-size: 10pt"> Such Subscriber acknowledges that the Offering may
involve tax consequences and that the contents of the Subscription Agreement do not contain tax advice or information. Such Subscriber
acknowledges that such Subscriber must retain such Subscriber&rsquo;s own professional advisors to evaluate the tax and other consequences
of an investment in the Securities. Such Subscriber intends to acquire the Securities without regard to tax consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
or Resale</U><FONT STYLE="font-size: 10pt">. Such Subscriber understands that the Securities have not been registered under the Securities
Act or the securities laws of any state and, as a result thereof, are subject to substantial restrictions on transfer. Such Subscriber
acknowledges that such Subscriber may be precluded from selling or otherwise disposing of the Securities for an indefinite period of
time and that in no circumstance may the Securities be transferred to any U.S. Person for six (6) months. Such Subscriber understands
and hereby acknowledges that the Company is under no obligation to register the Securities under the Securities Act. Such Subscriber
consents that the Company may, if it desires, permit the transfer of the Securities out of Subscriber&rsquo;s name only when Subscriber&rsquo;s
request for transfer is accompanied by an opinion of counsel reasonably satisfactory to the Company that neither the sale nor the proposed
transfer results in a violation of the Securities Act or any applicable state &ldquo;blue sky&rdquo; laws. Such Subscriber also understands
that sales or transfers of the Securities are further restricted by the Confidentiality Agreement (as defined below). Such Subscriber
acknowledges and agrees that such Subscriber will not sell or transfer the Securities to any Person prior to the earlier of (i) the date
on which public disclosure of the Confidential Information, as defined and covered by the Confidentiality Agreement, is made in accordance
with terms of the Confidentiality Agreement or (ii) <FONT>[ , 2023]</FONT>. Notwithstanding any of the
foregoing, such Subscriber acknowledges that the Company may refuse to register any transfer of the Securities if such transfer is not
made in accordance with the provisions of this Regulation S under the Securities Act or this <U>Section 3(j)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Due
Authorization; Enforcement</U><FONT STYLE="font-size: 10pt">. Such Subscriber has all requisite power and authority (and in the case
of an individual, capacity) to purchase and hold the Securities, to execute, deliver and perform such Subscriber&rsquo;s obligations
under this Subscription Agreement and when executed and delivered by such Subscriber, this Subscription Agreement will constitute legal,
valid and binding agreements of such Subscriber enforceable against such Subscriber in accordance with their terms, except as enforceability
may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&rsquo; and contracting
parties&rsquo; rights generally, and except as enforceability may be subject to general principles of equity (regardless of whether such
enforceability is considered in a proceeding in equity or at law).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Address</U><FONT STYLE="font-size: 10pt">.
The residence address of such Subscriber furnished by such Subscriber on the signature page hereto is such Subscriber&rsquo;s principal
residence if such Subscriber is an individual or its principal business address if it is a corporation, partnership, trust or other entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance
with Laws</U>. Such Subscriber will comply with all applicable laws and regulations in effect in any jurisdiction in which such Subscriber
purchases or sells Securities and obtain any consent, approval or permission required for such purchases or sales under the laws and regulations
of any jurisdiction to which such Subscriber is subject or in which such Subscriber makes such purchases or sales, and the Company shall
have no responsibility therefore. Such Subscriber shall not effect any transactions in the Company&rsquo;s securities other than the purchase
of the Securities while Subscriber is in possession of material non-public information, until such time all material non-public information
has been disclosed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 40pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 40pt"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 40pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(n) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accuracy
of Representations and Warranties</U><FONT STYLE="font-size: 10pt">. The information set forth herein concerning such Subscriber is true
and correct. Such Subscriber understands that, unless such Subscriber notifies the Company in writing to the contrary at or before the
Closing, each of such Subscriber&rsquo;s representations and warranties contained in this Subscription Agreement will be deemed to have
been reaffirmed and confirmed as of the Closing, taking into account all information received by such Subscriber.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entity
Representation<FONT STYLE="font-size: 10pt">.</FONT></U><FONT STYLE="font-size: 10pt"> If such Subscriber is a corporation, partnership,
trust or other entity, such entity further represents and warrants that it was not formed for the purpose of investing in the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;Confidentiality</U><FONT STYLE="font-size: 10pt">.
Such Subscriber has executed and delivered to the Company that certain Confidentiality Agreement in the form attached hereto as <B><U>Annex
A</U></B> (the &ldquo;<U>Confidentiality Agreement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: 36pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Company</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The Company represents and warrants
to each Subscriber that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization</U><FONT STYLE="font-size: 10pt">.
The Company is organized and validly existing in good standing under the laws of the state of Delaware. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Due
Authorization, Enforcement and Valid Issuance</U><FONT STYLE="font-size: 10pt">. The Company has all requisite power and authority to
execute, deliver and perform its obligations under this Subscription Agreement, and when executed and delivered by the Company, this
Subscription Agreement will constitute legal, valid and binding agreements of the Company enforceable against the Company in accordance
with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws
affecting creditors&rsquo; and contracting parties&rsquo; rights generally, and except as enforceability may be subject to general principles
of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). The Securities have been duly
authorized and, when issued and paid for in accordance with the terms of this Subscription Agreement, will be duly and validly issued,
fully paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Noncontravention<FONT STYLE="font-size: 10pt">.
</FONT></U><FONT STYLE="font-size: 10pt">The execution and delivery of this Subscription Agreement and the consummation of the transactions
contemplated hereby will not conflict with or constitute a violation of, or default under (i) any material agreement to which the Company
is a party or by which it or any of its properties are bound or (ii) the organizational documents of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 40pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 40pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: 0cm">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions
to Obligations of each Subscriber and the Company</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">The
obligations of each Subscriber to purchase and pay for the Securities specified on the signature page hereto and of the Company to sell
the Securities are subject to the satisfaction at or prior to the Closing of the following conditions precedent: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties</U>. The representations and warranties of such Subscriber contained in <U>Section 3</U> hereof and of the Company contained
in <U>Section 4</U> hereof shall be true and correct as of the Closing in all respects with the same effect as though such representations
and warranties had been made as of the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: 0cm">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Legends</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">The
certificates representing the Securities sold pursuant to this Subscription Agreement will be imprinted with legends in substantially
the following form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 36pt; text-align: justify">&ldquo;THE SECURITIES REPRESENTED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;ACT&rdquo;) AND MAY NOT BE SOLD OR TRANSFERRED EXCEPT
IN ACCORDANCE WITH REGULATION S PROMULGATED UNDER THE ACT. IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR AN OPINION
OF COUNSEL SATISFACTORY TO THE CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED. HEDGING TRANSACTIONS INVOLVING THE SECURITIES REPRESENTED
BY THIS CERTIFICATE MAY NOT BE CONDUCTED EXCEPT IN COMPLIANCE WITH THE ACT.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certificates may also bear any other legend language
that may be determined by the Company and its counsel from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>United
States Anti-Money Laundering Program.</U> Each Subscriber understands that the Company&rsquo;s Board of Directors is required to comply
with applicable anti-money laundering provisions under the United States PATRIOT Act of 2001, as amended (the &ldquo;<U>USA PATRIOT Act</U>&rdquo;).
As a condition to acceptance of each Subscriber&rsquo;s investment in the Company, such Subscriber makes the representations and agreements
set forth on <B><U>Annex B</U></B> attached hereto, and agrees to provide to the Company true and correct copies of the applicable documentation
pursuant to the requirements of <B><U>Annex C</U></B>, attached hereto. The Company reserves the right to request such additional information
as is necessary to verify the identity of each Subscriber and the underlying beneficial owner of such Subscriber&rsquo;s interest in the
Company. In the event of delay or failure by such Subscriber to produce any information required for verification purposes, the Company
may refuse to accept a subscription or may cause the withdrawal of such Subscriber from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice<FONT STYLE="font-size: 10pt">.
</FONT></U><FONT STYLE="font-size: 10pt">Any notices, consents, waivers or other communications required or permitted to be given under
the terms of this Subscription Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered
personally; (ii) upon receipt, when sent by email or facsimile (provided confirmation of transmission is mechanically or electronically
generated and kept on file by the sending party); or (iii) one (1) business day after deposit with an overnight courier service, in each
case properly addressed to the party to receive the same. The addresses, email and facsimile numbers for such communications shall be:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108pt">If to the Company:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enochian BioSciences Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt">9480 NE 2nd Ave, #73</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt">Miami, FL 33138</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt">Phone: (305) 918-1980</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt">E-mail: lpuche@enochianbio.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt">Attention: Luisa Puche</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt; text-indent: -108pt">with a copy to:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;K&amp;L Gates LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt">200 South Biscayne Boulevard</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt">Suite 3900</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt">Miami, FL 33131</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt">Facsimile:&#9;(305) 359-3306</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt">E-mail: clayton.parker@klgates.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt">Attention: Clayton E. Parker, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 216pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">If to a Subscriber, to its residence address
(or mailing address, if different), email and facsimile number set forth at the end of this Subscription Agreement, or to such other address,
email and/or facsimile number and/or to the attention of such other individual as specified by written notice given to the Company five
(5) calendar days prior to the effectiveness of such change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement; Amendment<FONT STYLE="font-size: 10pt">.</FONT></U><FONT STYLE="font-size: 10pt"> This Subscription Agreement and the Confidentiality
Agreement, supersede all other prior oral or written agreements between each Subscriber, the Company, their affiliates and Persons acting
on their behalf with respect to the matters discussed herein, and constitutes the entire understanding of the parties with respect to
the matters covered herein. No provision of this Subscription Agreement may be amended or waived other than by an instrument in writing
signed by the Company and each Subscriber.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability<FONT STYLE="font-size: 10pt">.
</FONT></U><FONT STYLE="font-size: 10pt">If any provision of this Subscription Agreement shall be invalid or unenforceable in any jurisdiction,
such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Subscription Agreement in
that jurisdiction or the validity or enforceability of any provision of this Subscription Agreement in any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U><FONT STYLE="font-size: 10pt">. This Subscription Agreement shall be governed by and construed in accordance with the laws of
the state of Delaware, without giving effect to any choice of law or conflict of law provision or rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Consent to Personal
Jurisdiction and Venue; Waiver of Jury Trial; Waiver of Service of Process</U><FONT STYLE="font-size: 10pt">. Each Subscriber hereby
consents to personal jurisdiction and exclusive venue in the Circuit Court in and for Miami-Dade County, Florida. <B>Furthermore, each
Subscriber and Company hereby expressly waive a trial by jury in any action between such Subscriber and the Company arising out of or
in connection with this Agreement.</B> For purposes of this Section, the term &ldquo;Subscriber&rdquo; includes any business entity owned
or controlled by the Subscriber. Each party hereby irrevocably waives personal service of process and consents to process being served
in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such Notices on this signature page
of this Subscription Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.
Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns<FONT STYLE="font-size: 10pt">.</FONT></U><FONT STYLE="font-size: 10pt"> This Subscription Agreement shall be binding upon
and inure to the benefit of the parties and their respective successors and assigns. A Subscriber shall not assign its rights hereunder
without the prior written consent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Third Party Beneficiaries</U><FONT STYLE="font-size: 10pt">. This Subscription Agreement is intended for the benefit of the parties hereto
and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any
other Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notification
of Changes</U>. Each Subscriber hereby covenants and agrees to notify the Company upon the occurrence of any event prior to the closing
of the purchase of the Securities pursuant to this Subscription Agreement which would cause any representation, warranty or covenant of
such Subscriber contained in this Subscription Agreement to be false or incorrect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Further
Assurances</U><FONT STYLE="font-size: 10pt">. Each party shall do and perform, or cause to be done and performed, all such further acts
and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may
reasonably request in order to carry out the intent and accomplish the purposes of this Subscription Agreement and the consummation of
the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Legal
Representation<FONT STYLE="font-size: 10pt">.</FONT></U><FONT STYLE="font-size: 10pt"> Each Subscriber acknowledges that: (i) such Subscriber
has read this Subscription Agreement and the annexes referred to herein; (ii) such Subscriber understands that the Company has been represented
in the preparation, negotiation and execution of the Subscription Agreement; and (iii) such Subscriber understands the terms and conditions
of the Subscription Agreement and is fully aware of their legal and binding effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses</U><FONT STYLE="font-size: 10pt">.
Each party will bear its own costs and expenses (including legal and accounting fees and expenses) incurred in connection with this Subscription
Agreement and the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U><FONT STYLE="font-size: 10pt">.
This Subscription Agreement may be executed in counterparts, all of which shall be considered one and the same agreement. The exchange
of signature pages by electronic signature, by electronic mail in &ldquo;portable document format&rdquo; (&ldquo;.pdf&rdquo;) form or
by any other electronic means intended to preserve the original graphic and pictorial appearance of a document shall constitute effective
execution and delivery of this Agreement as to the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[<I>SIGNATURE PAGES FOLLOW</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SUBSCRIBER SIGNATURE PAGE TO SUBSCRIPTION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF,</B> and
intending to be legally bound hereby, each Subscriber has caused this Subscription Agreement to be duly executed as of as of the date
first set forth above, and by executing this signature page, hereby executes, adopts and agrees to all terms, conditions, and representations
contained in the foregoing Subscription Agreement and hereby subscribes for the Securities offered by the Company in the amount set forth
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSCRIBER:</B></FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print Name</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares (number of shares of Common Stock subscribed for):
____________<BR></FONT></P>

<P STYLE="margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants (number of Warrants subscribed for): <U>[an amount
equal to 50% of the Shares]</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Residence Address:</FONT></TD>
<TD STYLE="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="width: 40%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mailing Address, if different from Residence Address:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>COMPANY SIGNATURE PAGE TO SUBSCRIPTION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><B>IN WITNESS WHEREOF,</B> and
intending to be legally bound hereby, Enochian Biosciences Inc. has caused this Subscription Agreement to be duly executed as of as of
the date first set forth above, and by executing this signature page, hereby executes, adopts and agrees to all terms, conditions, and
representations contained in the foregoing Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Accepted and Agreed:</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENOCHIAN BIOSCIENCES INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Annex
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 13; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Annex
B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>UNITED STATES ANTI-MONEY LAUNDERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;REPRESENTATIONS AND WARRANTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the acquisition of the Company&rsquo;s
Securities, each Subscriber hereby represents, warrants and covenants to the Company as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such Subscriber
has reviewed the website of the U.S. Treasury Department<I>&rsquo;</I>s Office of Foreign Assets Control (&ldquo;OFAC&rdquo;), and conducted
such other investigation as such Subscriber deems necessary or prudent, prior to making these representations and warranties. Such Subscriber
acknowledges that U.S. federal regulations and executive orders administered by OFAC prohibit, among other things, engaging in transactions
with, and the provision of services to, certain foreign countries, territories, entities and individuals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All evidence
of identity provided in connection with such Subscriber<I>&rsquo;</I>s acquisition of Securities is genuine and all related information
furnished is accurate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such Subscriber
understands and agrees that the investment of funds is prohibited by or restricted with respect to any persons or entities: (i) acting,
directly or indirectly, on behalf of terrorists or terrorist organizations, including those persons, entities and organizations that are
included on any of the OFAC lists; (ii) residing or having a place of business in a country or territory named on such lists or which
is designated as a Non-Cooperative Jurisdiction by the Financial Action Task Force on Money Laundering (&ldquo;FATF&rdquo;), or whose
subscription funds are transferred from or through such a jurisdiction; (iii) (A) that are a &ldquo;Foreign Shell Bank&rdquo; within the
meaning of the USA PATRIOT Act or (B) that are a foreign bank other than a &ldquo;Regulated Affiliate&rdquo; that is barred, pursuant
to its banking license, from conducting banking activities with the citizens of, or with the local currency of, the country that issued
the license or (C) whose subscription funds are transferred from or through the entities listed in foregoing clauses (A) and (B); or (iv)
residing in, or organized under the laws of, a jurisdiction designated by the Secretary of the Treasury under Sections 311 or 312 of the
USA PATRIOT Act as warranting special measures due to money laundering concerns. Such persons or entities in (i) through (iv) are collectively
referred to as &ldquo;Restricted Persons.&rdquo; Neither such Subscriber, nor any person or entity controlling, controlled by, or under
common control with, such Subscriber, any investors in such Subscriber (if such Subscriber is a pooled investment vehicle) or any person
or entity for whom such Subscriber is acting as agent, representative, intermediary, nominee or similar capacity (each such investor in
such Subscriber and each such person for whom such Subscriber acts as agent, representative, intermediary, nominee or in a similar capacity,
an &ldquo;Underlying Beneficial Owner&rdquo;) in connection with the acquisition of Securities is a Restricted Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No funds
tendered for the acquisition of Securities are directly or indirectly derived from activities that may contravene U.S. federal, state
or non-U.S. laws and regulations, including anti-money laundering laws, rules and regulations, and no capital contribution in relation
to Securities acquired by such Subscriber or, if applicable, any Underlying Beneficial Owner will be derived from any illegal or illegitimate
activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the
extent such Subscriber has any Underlying Beneficial Owners, such Subscriber: (i) has carried out thorough due diligence as to, and established
the identities of, the Underlying Beneficial Owners and any related persons to the extent required by applicable law and regulations (&ldquo;Related
Persons&rdquo;); (ii) holds the evidence of such identities and will maintain all such evidence for at least five years from the date
of the completion of the liquidation of the Company; and (iii) will make such information available to the Company upon the Company&rsquo;s
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such Subscriber
acknowledges and understands that the Company, in its sole discretion, may decline to accept any subscription for Securities by a person
who is a &ldquo;Covered Person&rdquo; within the meaning of the Guidance on Enhanced Scrutiny for Transactions that May Involve the Proceeds
of Foreign Official Corruption, issued by the U.S. Department of the Treasury, <I>et al.</I>, January, 2001. Accordingly, such Subscriber
agrees to inform the Company, prior to its acquisition of Securities, if such Subscriber or any person controlling, controlled by, or
under common control with, such Subscriber, or for whom such Subscriber is acting as agent or nominee in connection with the acquisition
of Securities, is a Covered Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such Subscriber
agrees to provide any information (including confidential information about such Subscriber and, if applicable, any Underlying Beneficial
Owner or Related Person) to any person deemed necessary by the Company, in its sole and absolute discretion, to comply with its anti-money
laundering responsibilities and policies and any laws, rules and regulations applicable to an investment held or proposed to be held by
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such Subscriber
authorizes and permits the Company, using its own reasonable business judgment, to report information about such Subscriber, or any person
controlling, controlled by, or under common control with such Subscriber, to appropriate authorities, and such Subscriber agrees not to
hold them liable for any loss or injury that may occur as the result of providing such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such Subscriber
agrees that, in the event of a material change with respect to the information provided in connection with the purchase of the Securities,
such Subscriber will provide the Company promptly with updated information affected by the material change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
Subscriber agrees that, notwithstanding any statement to the contrary in any agreement into which it has entered that relates to the Company,
or any statement to the contrary in any private placement memorandum of the Company, if the Company determines that such Subscriber has
appeared on a list of known or suspected terrorists or terrorist organizations compiled by any U.S. or non-U.S. governmental agency, or
that any information provided by such Subscriber in connection with the acquisition of Securities is no longer true or accurate, the Company,
without limiting any other rights available under any agreement between the Company and such Subscriber, shall be authorized to take any
action it deems necessary or appropriate as a result thereof. The Company may be obligated to &ldquo;freeze the account&rdquo; of such
Subscriber, either by prohibiting additional capital contributions, restricting any distributions and/or declining any requests to transfer
such Subscriber&rsquo;s Securities. In addition, in any such event, such Subscriber may forfeit its Securities, may be forced to withdraw
from the Company or may otherwise be subject to the remedies required by law, and such Subscriber shall have no claim against the Company
nor its officers, directors, employees, agents, control persons, affiliates and professional advisors and such parties shall be held harmless
and indemnified by such Subscriber in accordance with the indemnification section of this Agreement for any form of damages as a result
of any of the actions described in this paragraph. The Company may also be required to report such action and to disclose such Subscriber&rsquo;s
identity or provide other information with respect to such Subscriber to OFAC or other governmental entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
Subscriber acknowledges and agrees that any distributions paid to it by the Company will be paid to, and any contributions made by it
to the Company will be made from, an account in such Subscriber&rsquo;s name unless the Company, in its sole discretion, agrees otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
Subscriber understands, acknowledges and agrees that the acceptance of this Agreement, together with the appropriate remittance, will
not breach any applicable money laundering or related rules or regulations (including, without limitation, any statutes, rules or regulations
in effect under the laws of the U.S.A. pertaining to prohibitions on money laundering or to transacting business or dealing in property
that may be blocked or may belong to Specially Designated Nationals, as such term is used by OFAC).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Annex
C</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ANTI-MONEY LAUNDERING DOCUMENTATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Each Subscriber has delivered, or is concurrently delivering herewith,
the true, correct and applicable documentation noted below that is applicable to such Subscriber:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">&nbsp;</TD>
<TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Individuals </B>(<U>each</U> of the following):</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt">&nbsp;</TD>
<TD STYLE="width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified (notarized) copy of passport or other valid government identification document displaying the true name, signature, date of birth and photograph of such Subscriber (with certified English translation, if necessary); and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copy of a recent bank statement or utility bill showing such Subscriber&rsquo;s current home address.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify; text-indent: -22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">&nbsp;</TD>
<TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate </B>(<U>each</U> of the following):</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt">&nbsp;</TD>
<TD STYLE="width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation (or equivalent) with evidence of any name changes;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Good Standing;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director resolution authorizing the investment, if applicable;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(D)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current list or register of Directors;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(E)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen signatures of persons authorized to bind such Subscriber with regard to its investments with name and office held printed underneath or Powers of Attorney or Letters of Authority (if applicable);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(F)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information on at least two Directors (see (i) above for individuals and (ii) for all other entities);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(G)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evidence of identity for authorized signatories and all beneficial owners of such Subscriber &gt;25% OR comfort letter (see (i) above for individuals and (ii) for all other entities); and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(H)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signed copy of such Subscriber&rsquo;s latest available financial statements.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify; text-indent: -22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">&nbsp;</TD>
<TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limited Partnership</B> (or <B>Limited Liability Company</B>) (<U>each</U> of the following):</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt">&nbsp;</TD>
<TD STYLE="width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Limited Partnership (or equivalent) (evidencing registered address) with evidence of any name changes;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified copy of the limited partnership agreement (or equivalent);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limited partnership mandate (or equivalent) for making the investment (if any);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(D)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen signatures of persons authorized to bind such Subscriber with regard to its investments with name and office held printed underneath or Powers of Attorney or Letters of Authority (if applicable);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(E)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information on the individual(s) that control the general partner (or managing member, if applicable) (see (i) above for individuals and (ii) for all other entities);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(F)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evidence of identity for authorized signatories and all beneficial owners of such Subscriber &gt;25% OR comfort letter (see (i) above for individuals and (ii) for all other entities); and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(G)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signed copy of such Subscriber&rsquo;s latest available financial statements.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify; text-indent: -22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify; text-indent: -22.5pt"></P>

<!-- Field: Page; Sequence: 16; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify; text-indent: -22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">&nbsp;</TD>
<TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trust </B>(<U>each</U> of the following):</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt">&nbsp;</TD>
<TD STYLE="width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified copy of Trust Deed/Agreement (including trust name, nature of trust, trustees, authorizations, date of trust and principal address);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information about the trustee(s) and settlor(s) (or beneficial owner(s), if different than the settlor(s)) (see (i) above for individuals and (ii) for all other entities); and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signed copy of such Subscriber&rsquo;s latest available financial statements.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify; text-indent: -22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">&nbsp;</TD>
<TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Private Pension Plans or Not For Profit (including Foundations and Charities)</B> (<U>each</U> of the following):</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt">&nbsp;</TD>
<TD STYLE="width: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified copy of the entity&rsquo;s formation documents;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An explanation of the nature of the entity&rsquo;s purpose and operations;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evidence of identity for authorized signatories, anyone who gives instructions on behalf of the entity and all beneficial owners of such Subscriber &gt;25% OR comfort letter (see (i) above for individuals and (ii) for all other entities); and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(D)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confirmation of not for profit designation from the applicable government authority.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-align: justify; text-indent: -22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt">&nbsp;</TD>
<TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial Institutions</B> (additional requirements):</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify">In addition to the applicable requirements
above, banks, brokers and other financial institutions must deliver a representation letter in the form determined by the Company indicating
that they have established and implemented anti-money laundering procedures reasonably designed to achieve compliance with the USA PATRIOT
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each Subscriber acknowledges that the Company and
its affiliates may require further identification of such Subscriber or source of funds before the subscription can be processed, and
the Company and its officers, directors, employees, agents, control persons, affiliates and professional advisors shall be held harmless
and indemnified in accordance with the indemnification provisions of the Subscription Agreement as a result of a failure to process the
subscription if such information as has been required by the Company has not been provided by such Subscriber. Such Subscriber agrees
to provide any information deemed necessary by the Company in its sole and absolute discretion to comply with its anti-money laundering
policies and obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C-2</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>e4510_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>EXHIBIT 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Enochian BioSciences&rsquo; CEO Letter to Shareholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Turning the Page; A Promising Future</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Los Angeles, April 3, 2023 (GLOBE NEWSWIRE) &ndash;(NASDAQ: ENOB)--</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD><FONT STYLE="font-size: 10pt"><I>Accelerated Pre-Investigational New Drug (Pre-IND) submission to the US Food and Drug Administration
(FDA) for potential cancer product due to additional promising results from studies in a commonly used mouse model</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD><FONT STYLE="font-size: 10pt"><I>Dr. Anahid Jewett, a leading cancer researcher from the University of California, Los Angeles (UCLA)
presented key results at the 8<SUP>th</SUP> Annual Innate Killer Summit last week (Link to presentation Excerpt)</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD><FONT STYLE="font-size: 10pt"><I>Pre-IND submission expanded to include a phase 1/2a safety and tolerability clinical study proposal
for all solid tumors to be narrowed to 3-4 most promising indications during a later stage trial </I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD><FONT STYLE="font-size: 10pt"><I>IND submission targeted for early 2024</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD><FONT STYLE="font-size: 10pt"><I>Cancer platform and product design, for many solid tumors, could also have application to other pipelines,
including infectious diseases, such as HIV</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD><FONT STYLE="font-size: 10pt"><I>Dr Saheed Sadeghi, Clinical Director for the UCLA Santa Monica Hematology-Oncology Community Practice
Group joined the development team as a consultant to help prepare for clinical activities</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD><FONT STYLE="font-size: 10pt"><I>Private Placement of restricted stock has secured approximately $2.5 million</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD><FONT STYLE="font-size: 10pt"><I>Plans in place and eligible to apply for non-dilutive capital of up to $27 million for IND-enabling
studies through clinical trials</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Dr. Anahid
Jewett, Professor at the University of California, Los Angeles (UCLA) and <FONT STYLE="font-weight: normal; color: #2D3047">a renowned
cancer researcher</FONT></I></FONT><FONT STYLE="color: #2D3047"><B>&nbsp;</B><FONT STYLE="font-weight: normal"><I>in the field of immunotherapy
</I></FONT></FONT><I><FONT STYLE="font-family: Times New Roman, Times, Serif">said, &ldquo;I have been working in this field for three
decades and designed the mouse model that we have used in my laboratory to study the Company&rsquo;s potential cancer therapies. The results
are some of the most impressive I have seen. The fact that we saw very similar highly statistically significant results across two independently
conducted studies is particularly encouraging, indicating reproducibility of the findings. I look forward to continuing our work together
towards clinical trials, and potentially offering hope to many who are suffering with diseases with few good treatment options.&rdquo;</FONT></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&ldquo;I am delighted to be the Senior Scientific Advisor for Enochian
BioSciences,&rdquo; said Dr. Richard Whitley, <FONT STYLE="font-weight: normal; color: #2D3047">Distinguished Professor of Pediatrics,
Professor of Microbiology, Medicine and Neurosurgery and Loeb Eminent Scholar Chair in Pediatrics of the University of Alabama</FONT>.
&ldquo;I have been very impressed by the Company&rsquo;s resilience and the potential human impact of the recent data from the cancer
pipeline with a potential product that could have relevance for other pipelines in HIV, and perhaps other chronic infectious diseases.
I very much look forward to working with the Company as they advance the translation of their platform to potential life-saving interventions
for cancer and infectious diseases.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Dear Shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On behalf of the Board, Management, and scientific team, I would like to
thank two distinguished leaders in their fields, Professors Anahid Jewett, Ph.D. and Richard Whitley, MD, for their steadfast support
and belief in the promising future of the Company. In addition, we offer deep thanks to Dr. Jewett and her colleagues at UCLA for performing
the pivotal proof-of-concept studies that have allowed us to accelerate our timeline to submit a Pre-Investigational New Drug (Pre-IND)
application to the US FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I would also like to thank and welcome Dr. Sadeghi to the team. He brings
deep experience and expertise as a consultant as we prepare for the IND submission, and we hope, clinical trials in early 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I am pleased to be able to provide shareholders with a summary of recent
advances and what we believe is a promising future for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Proof-of-Concept Confirmed for Novel Cell-Gene-Immunotherapy for
Pancreatic Cancer and, Potentially, Other Solid Tumors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Several key, independent studies performed by Dr. Anahid Jewett have shown
remarkably promising results, demonstrating proof-of-concept. In two separate studies in humanized mice implanted with pancreatic cancer,
the volume of the tumors was reduced by an average of 77 to 87 percent following only two injections of the product. The tumor weight
was also highly statistically significantly reduced. There was also a statistically significant increase in key immunologic markers in
mice potentially validating the hypothesized mechanism of action via a strong activation of the immune response by the potential product.
Of note, the mice were evaluated only 3-4 weeks after treatment &ndash; it is possible the effect would have been even greater if the
study were conducted for a longer time. As noted above, Dr. Jewett presented the key results as part of an invited plenary lecture at
a scientific conference last week ( Link to Press Release and Link to Presentation Excerpt).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Accelerated Timeline for Pre-IND Submission, Toward Several Solid
Tumors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Because of the strength of the data, we are accelerating the timeline for
a Pre-IND submission to the US FDA, which is imminent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Because the mechanism of action could be effective against other solid
tumors, the clinical study design component of the Pre-IND submission will propose the inclusion of all solid tumors during the initial
safety and tolerability component and based on preliminary anti-cancer performance, narrowed to a few solid tumor candidates such as pancreatic,
triple-negative breast cancers, head and neck, and mesothelioma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Each of those cancers have relatively few treatment options with poor life-expectancy.
For example, the 5-year survival rate for pancreatic cancer is only 10 percent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are targeting submission of the IND application for early 2024 towards
potentially starting clinical trials soon after that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Basic Platform and Product Design Leveraged for Other Pipelines Such
as Infectious Diseases, Including HIV</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The second proof-of-concept study was performed with what we believe will
be the key product design components that we intend to advance towards clinical studies. Important features of that design provide the
backbone of our overall approach to use cells from other persons, with or without gene-modification, to renew and stimulate a stronger
immune response than the patient could without treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have a similar approach to HIV which could apply to other chronic infectious
disease conditions. Therefore, we can potentially leverage the design, development, production, and regulatory processes of the oncology
platform for HIV pipelines, and, perhaps, for additional infectious diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Private Placement and Non-Dilutive Opportunities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of March 31, 2023, we raised approximately $2.5 million of additional
funds through a private placement of restricted shares. The Chair of the Board, Ren&eacute; Sindlev, led the round with $1 million, demonstrating
his confidence in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have identified a total of up to $27 million from three non-dilutive
grant opportunities covering IND-enabling (Pre-IND to IND) and clinical (post IND) costs. There is, of course, no guarantee of being awarded
any of the grants. But we believe the strength of the data puts the Company in a strong position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Conclusion: Turning the Page for a Promising Future While Working
to Maximize Shareholder Value</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Despite significant challenges that would have derailed many companies,
our strategic plan to focus on our most promising platform has allowed us to significantly de-risk our cancer immune oncology program
and be in a strong position now. We have made substantial scientific and product development advances over the past 10 months. This was
accomplished while substantially reducing operating costs &ndash; including, at my request, a decrease in my compensation as CEO - towards
maximizing shareholder value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The progress with a platform that has key attributes that could potentially
be leveraged for products to treat solid tumors, HIV and, perhaps, other infectious diseases is particularly encouraging. Such an approach
could open possibilities to partner, sell or sub-license individual pipelines towards further potential maximization of shareholder value.
Indeed, as previously announced, we have already sub-licensed a novel aspect of one of our HIV pipelines to potentially enhance the effectiveness
of a CAR-T therapy already in clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Recent fundraising through a private placement of approximately $2.5 million
and the identification of potential non-dilutive grant opportunities totaling up to $27 million are encouraging and, yet again, offer
the possibility to maximize shareholder value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Thank you for taking the time to read this update. We look forward to your
continued support as we work towards life-saving scientific advances and a promising new future for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>The Hon. Mark Dybul, MD<BR>
Chief Executive Officer, Enochian BioSciences Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Forward-Looking Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Statements in this press release that are not strictly
historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations
and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements
other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as
&ldquo;believes,&rdquo; &ldquo;plans,&rdquo; &ldquo;expects,&rdquo; &ldquo;aims,&rdquo; &ldquo;intends,&rdquo; &ldquo;potential,&rdquo;
or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties,
including as set forth in Enochian BioSciences&rsquo; most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned
not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements
are qualified in their entirety by this cautionary statement, and Enochian BioSciences Inc. undertakes no obligation to revise or update
this shareholder letter to reflect events or circumstances after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Contact: ir@enochianbio.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Source: Enochian Biosciences Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>enob-20230330.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /aBZs7xRiXgOn8uGanZcSa+M6aPtzp51+ekxvGZ+fVlaryUlyptFGih+kSHW0X0O -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:ENOB="http://enochianbio.com/20230330" elementFormDefault="qualified" targetNamespace="http://enochianbio.com/20230330">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://enochianbio.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="enob-20230330_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="enob-20230330_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>enob-20230330_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>enob-20230330_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://enochianbio.com/role/Cover" xlink:href="enob-20230330.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://enochianbio.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140706816935280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 30,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-54478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ENOCHIAN
BIOSCIENCES INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001527728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-2559340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1927
Paseo Rancho Castilla<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Los
Angeles<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">918-1980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENOB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>e4510_8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="enob-20230330.xsd" xlink:type="simple"/>
    <context id="From2023-03-30to2023-03-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2023-03-30</startDate>
            <endDate>2023-03-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-03-30to2023-03-30">0001527728</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-03-30to2023-03-30">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-03-30to2023-03-30">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-03-30to2023-03-30">2023-03-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-03-30to2023-03-30">ENOCHIAN BIOSCIENCES INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-03-30to2023-03-30">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-03-30to2023-03-30">000-54478</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-03-30to2023-03-30">45-2559340</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-03-30to2023-03-30">1927 Paseo Rancho Castilla</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-03-30to2023-03-30">Los Angeles</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-03-30to2023-03-30">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-03-30to2023-03-30">90032</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-03-30to2023-03-30">(305)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-03-30to2023-03-30">918-1980</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-03-30to2023-03-30">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-03-30to2023-03-30">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-03-30to2023-03-30">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-03-30to2023-03-30">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-03-30to2023-03-30">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-03-30to2023-03-30">ENOB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-03-30to2023-03-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-03-30to2023-03-30">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MO-5N [P;&)D5F\ZE-+"%+0XWC,(+82^ [U=2FO>!W<>6/T.,_@502P,$%
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " "$2H-6F5R<(Q &  "<)P  $P
M            @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M (1*@U97HQG@7@0  )(0   8              " @0T(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " "$2H-6GZ ;\+$"  #B#   #0
M            @ &A#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( (1*@U:7
MBKL<P    !,"   +              "  7T/  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( (1*@U:JQ"(6,P$  "("   /              "  680  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " "$2H-6)!Z;HJT   #X 0  &@
M        @ '&$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " "$2H-699!YDAD!  #/ P  $P              @ &K$@  6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #U$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="e4510_8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enochianbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="e4510_8-k.htm">e4510_8-k.htm</File>
    <File>e4510_ex10-1.htm</File>
    <File>e4510_ex4-1.htm</File>
    <File>e4510_ex99-1.htm</File>
    <File>enob-20230330.xsd</File>
    <File>enob-20230330_lab.xml</File>
    <File>enob-20230330_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "e4510_8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "e4510_8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "enob-20230330_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "enob-20230330_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "enob-20230330.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ENOB",
   "nsuri": "http://enochianbio.com/20230330",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e4510_8-k.htm",
      "contextRef": "From2023-03-30to2023-03-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://enochianbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e4510_8-k.htm",
      "contextRef": "From2023-03-30to2023-03-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://enochianbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001731122-23-000552-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-23-000552-xbrl.zip
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MN!0RF-V,-/N,>H'+]D+[W(8V$;#H51(%0IL#7QK[7!2A$$2C%^.8.)49/.
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M*1:'328KR<*%>]*]C,N_M:>7FR"]JI<KR4CX)<E-'.Q,>A/=&3/ 5 #FA6]
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ML?%13/,DS;V(QKR0XSQDFAF('*:0T&L&TL\3&!Q6U867PR'LOWS^'!Z'=\-
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M\3SV2(Q<40J#2C]1)+90=[XF?2&1?CQ&8>R0D0W*U8/OH-3$X36J1^)*C:]
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MTR?BJNL*KM2E"6I?<*-K>[ @#L_50<XS<1GRAC?4A'S3732R27SPZQ?<[SD
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MY%O O*:J_HH^GREC2]8M*@;,)(4+-&&5$3"WB@/N:<%EV]:@H^PKE?CY)"4
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MRD8_E;Y1P3'WA>%\^<K0F/#B>N.I"0PE).J<63TFA;UPW=N/G(N%J[2TND$
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MS59/'P&6 24PH140&(I_.$YPU)&C:>);!C=PQ."?*.Z#$J*N%WD:X]&%GX'
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M+3*LFI;7*]P@BA5$<82[T0>*>'^PR*_C*\XYZE.$0<_-P93;]@@/.>NK%O)
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M7^G3P[/C7XDWG4S?G1[\'U!+ P04    " "$2H-67D1E&S\4   640  $
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MWP*YH%9KV+-9C!&I4 [P6/ CV(0F37$E65I9$$B_*ME!*]F6@I78BR$"42\
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MS6*H< ]Z[&-&3)(%0/WF2;VBK4Q)M\.^!X:&@#>B9"AK''+RK88*KIBA+4\
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M6!_$AV!:X=BP1W3!=O"\%JC;L9I>_@502P,$%     @ A$J#5H#Y9_K^"@
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M\8^M.&,G/-WW0M%2NN8"L&JB8<B"HL/N#02DDOME9,DQS1(Y@/5"TI8Z/]T
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MQ"'PZ(P,&C_)**3#RBMA7DCZQM(MS3$OWB7GMI$)T+DE![#9),80!42*W1E
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M-F/YO)@G'QJ7V=Q8]+1XQ.( WF[S3,Z@PAA\%;PSR/'MA0$-,&XR=$0$A-X
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MQ&JW_ ]02P$"% ,4    " "$2H-6\L-P1@,6  "+?P  #0
M@ $     930U,3!?."UK+FAT;5!+ 0(4 Q0    ( (1*@U;Y#T06P#X  !"A
M 0 0              "  2X6  !E-#4Q,%]E>#$P+3$N:'1M4$L! A0#%
M  @ A$J#5LOFP?!&*P  8M4   \              ( !'%4  &4T-3$P7V5X
M-"TQ+FAT;5!+ 0(4 Q0    ( (1*@U9>1&4;/Q0  !91   0
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2      < !P"Y 0  .ZL

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
